- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AAN’s 2023 Annual Meeting Will Include Education and Community, Says Dr David Spencer
David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University, previews the American Academy of Neurology (AAN) annual meeting for 2023 and says that attendees can expect not only to learn but also to leave feeling humbled and inspired.
Attendees can expect to leave the American Academy of Neurology (AAN) 75th annual meeting humbled and inspired, while participating in high-quality programming along the way, says David Spencer, MD, director of the Comprehensive Epilepsy Center and professor of neurology at Oregon Health and Science University.
Transcript
What can attendees look forward to at the AAN 2023 Annual Meeting?
The AAN has always been one of my favorite meetings to go to. I've been going pretty regularly for the last 20 years or so. I think people correctly think about it as being the premier place to go for cutting-edge research and hearing about what's hot off the press in neurology, which is correct.
They also have amazing educational programs, so that's been one of the things that I've really enjoyed going to. I work in a specialized field, so it's an opportunity to learn about things that I don't see every day. And the quality of the programming for education is really, really high.
I think also there's still a little bit of pent-up postpandemic need to get together and see people. So, it's always fun, at an in-person meeting, to just run across somebody in the hallway you haven't seen for a couple of years, meet up with people who are working in a similar area, and identify people who are potential collaborators and researchers in the future.
I always leave and have a mix of being humbled about everything that's happening that I'm not doing and inspired by a lot of new ideas.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
